 In a report issued on March 13,Mayank Mamtanifrom B.Riley FBR maintained aBuyrating on Medicinova MNOVResearch Report, with a price target of11.00. The companys shares closed last Monday at 4.03, close to its 52-week low of 2.79.Acc 